Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 31, 2022

SELL
$8.63 - $15.52 $187,063 - $336,411
-21,676 Reduced 47.97%
23,513 $208,000
Q2 2022

Jul 29, 2022

SELL
$8.59 - $20.77 $176,120 - $425,847
-20,503 Reduced 31.21%
45,189 $571,000
Q1 2022

Apr 29, 2022

BUY
$15.52 - $35.65 $68,381 - $157,073
4,406 Added 7.19%
65,692 $1.24 Million
Q4 2021

Feb 07, 2022

BUY
$28.89 - $35.33 $400,097 - $489,285
13,849 Added 29.19%
61,286 $2.15 Million
Q3 2021

Nov 01, 2021

BUY
$35.66 - $42.94 $219,522 - $264,338
6,156 Added 14.91%
47,437 $1.74 Million
Q2 2021

Aug 12, 2021

BUY
$23.7 - $39.27 $93,662 - $155,195
3,952 Added 10.59%
41,281 $1.62 Million
Q1 2021

May 13, 2021

SELL
$27.01 - $36.8 $152,579 - $207,883
-5,649 Reduced 13.14%
37,329 $1.06 Million
Q4 2020

Feb 04, 2021

BUY
$27.51 - $34.36 $408,633 - $510,383
14,854 Added 52.82%
42,978 $1.38 Million
Q3 2020

Nov 09, 2020

BUY
$25.8 - $34.61 $285,838 - $383,444
11,079 Added 65.0%
28,124 $908,000
Q2 2020

Jul 20, 2020

BUY
$17.65 - $28.05 $173,446 - $275,647
9,827 Added 136.15%
17,045 $470,000
Q1 2020

Apr 30, 2020

SELL
$15.19 - $29.51 $126,942 - $246,615
-8,357 Reduced 53.66%
7,218 $129,000
Q4 2019

Jan 28, 2020

BUY
$17.17 - $25.95 $119,503 - $180,612
6,960 Added 80.79%
15,575 $390,000
Q3 2019

Nov 04, 2019

SELL
$17.84 - $22.69 $18,910 - $24,051
-1,060 Reduced 10.96%
8,615 $154,000
Q2 2019

Jul 29, 2019

SELL
$22.0 - $31.78 $182,028 - $262,947
-8,274 Reduced 46.1%
9,675 $213,000
Q1 2019

Apr 29, 2019

BUY
$21.27 - $30.58 $151,655 - $218,035
7,130 Added 65.9%
17,949 $549,000
Q4 2018

Feb 01, 2019

BUY
$23.09 - $37.69 $249,810 - $407,768
10,819 New
10,819 $250,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.